Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 23.10.2019 | 13:55

Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

23-Oct-2019 / 13:55 CET/CEST
Update of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


 
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

Jena, October 23, 2019

As already announced on October 2, 2019, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,459 million in fiscal year 2018/19 (past year: EUR 1,280.9 million) and has significantly expanded EBIT[1] margin[2], exceeding the initial forecast of 15.0% to 17.5%. Based on today's new assessment, EBIT for fiscal year 2018/19 amounted to approx. EUR 264 million (past year: EUR 197.1 million), leading to an EBIT margin of 18.1%.

Upon publication of preliminary results on October 2, 2019, the company had anticipated a still higher EBIT margin for fiscal year 2018/19.

The shortfall was caused by higher operating expenses in the fourth quarter of fiscal year 2018/19, in part driven by the already announced higher investments in the fields of Surgical Ophthalmology and Digitalization.

Final results for fiscal year 2018/19 will be provided on December 6, 2019.
 
 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

[1] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation).
[2] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).


23-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

25. September 2020